echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J clin oncol: Risk of peritoneal cancer after salpingo-oophorectomy in BRCA1/2 pathogenic variant carriers

    J clin oncol: Risk of peritoneal cancer after salpingo-oophorectomy in BRCA1/2 pathogenic variant carriers

    • Last Update: 2022-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer with a 5-year survival rate of only 47 %
    .


    The average lifetime risk of EOC in women is 1.


    47

    Salpingo-oophorectomy (RRSO) is the most effective preventive method, reducing the risk of EOC by up to 96%
    .


    To optimize risk reduction, guidelines recommend that carriers of pathogenic variants in BRCA1 and BRCA2 receive RRSO at ages 35-40 and 40-45 years, respectively


    Salpingo-oophorectomy (RRSO) is the most effective preventive method, reducing the risk of EOC by up to 96%

    However, although the risk of ovarian cancer was significantly reduced after RRSO, the risk of developing peritoneal cancer (PC) remained
    .


    The etiology of peritoneal cancer has not been fully elucidated, but it may be related to serous tubal intraepithelial carcinoma (STIC)


    To assess the risk of peritoneal cancer in women with and without serous tubal intraepithelial carcinoma at the time of salpingo-oophorectomy


    We searched EMBASE, MEDLINE and Cochrane databases for studies published before September 2020 in women receiving RRSO who carry a BRA1/2 pathogenic variant
    .


    The primary outcome measures were the hazard ratio of developing peritoneal cancer in BRCA1/2 pathogenic variant carriers with and without STIC at the time of RRSO, and the risk of peritoneal cancer at 5 and 10 years after surgery


    The primary outcome measures were the hazard ratio of developing peritoneal cancer in BRCA1/2 pathogenic variant carriers with and without STIC at the time of RRSO, and the risk of peritoneal cancer at 5 and 10 years after surgery


    Cumulative risk of peritoneal cancer in patients with and without STIC

    Cumulative risk of peritoneal cancer in patients with and without STIC

    We screened 17 eligible studies covering a total of 3121 women, 115 of whom had serous tubal intraepithelial carcinoma at the time of salpingo-oophorectomy
    .


    During follow-up, the ratio of the risk of developing PC in patients with STIC to the risk of developing PC in individuals without STIC was estimated to be 33.


    3121 115 The ratio of the risk of developingPC in patients with STIC to the risk of developing PC in individuals without STIC was estimated to be 33.


    Predicted risk of peritoneal cancer in individuals with and without STIC

    Predicted risk of peritoneal cancer in individuals with and without STIC

    In conclusion, carriers of a BRCA1/2 pathogenic variant with serous tubal intraepithelial carcinoma at the time of salpingo-oophorectomy have an increased risk of subsequent peritoneal carcinoma over time


    BRCA1/2 pathogenic variant carriers with serous tubal intraepithelial carcinoma at the time of salpingo-oophorectomy and subsequently have an increased risk of developing peritoneal carcinoma over time having serous tubal at the time of salpingo-oophorectomy Carriers of a BRCA1/2 pathogenic variant in intraepithelial carcinoma have an increased risk of subsequent peritoneal carcinoma over time

     

    Original source:

    Original source:

    Miranda P.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.